Literature DB >> 22942350

Time until relapse in tuberculosis treatment trials: implication for phase 3 trial design.

John L Johnson, Bonnie A Thiel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22942350      PMCID： PMC3443806          DOI： 10.1164/ajrccm.186.5.464

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  2 in total

1.  Timing of relapse in short-course chemotherapy trials for tuberculosis.

Authors:  A J Nunn; P P J Phillips; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2010-02       Impact factor: 2.373

2.  Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

Authors:  John L Johnson; David Jamil Hadad; Reynaldo Dietze; Ethel Leonor Noia Maciel; Barrett Sewali; Phineas Gitta; Alphonse Okwera; Roy D Mugerwa; Mary Rose Alcaneses; Maria Imelda Quelapio; Thelma E Tupasi; Libby Horter; Sara M Debanne; Kathleen D Eisenach; W Henry Boom
Journal:  Am J Respir Crit Care Med       Date:  2009-06-19       Impact factor: 21.405
  2 in total
  3 in total

1.  Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Authors:  J Furin; E Alirol; E Allen; K Fielding; C Merle; I Abubakar; J Andersen; G Davies; K Dheda; A Diacon; K E Dooley; G Dravnice; K Eisenach; D Everitt; D Ferstenberg; A Goolam-Mahomed; M P Grobusch; R Gupta; E Harausz; M Harrington; C R Horsburgh; C Lienhardt; D McNeeley; C D Mitnick; S Nachman; P Nahid; A J Nunn; P Phillips; C Rodriguez; S Shah; C Wells; B Thomas-Nyang'wa; P du Cros
Journal:  Int J Tuberc Lung Dis       Date:  2016-03       Impact factor: 2.373

2.  Tuberculosis recurrence in a priority city in the state of São Paulo, Brazil.

Authors:  Amadeu Antonio Vieira; Danila Torres Leite; Solange Adreoni
Journal:  J Bras Pneumol       Date:  2017 Mar-Apr       Impact factor: 2.624

3.  Microevolution of Mycobacterium tuberculosis Subpopulations and Heteroresistance in a Patient Receiving 27 Years of Tuberculosis Treatment in Germany.

Authors:  Stefan Niemann; Matthias Merker; Lindsay Sonnenkalb; Gerald Strohe; Viola Dreyer; Sönke Andres; Doris Hillemann; Florian P Maurer
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.